Androgen priming in a poor ovarian stimulation response

Pshenisnova I.V., Yakovlev P.P.

1) “MD Medical Yaroslavl”, Yaroslavl, Russia; 2) Centre for Reproductive Medicine, Co. Ltd. “Next Generation Clinic”, Moscow, Russia
Despite the great progress in assisted reproductive technologies (ART), the poor ovarian stimulation (OS) response remains a major concern in reproductive medicine. It is supposed that the use of dehydroepiandrosterone and testosterone before therapy in poor female responders can improve the outcomes of ART programs due to a better OS response. At the same time, there are conflicting data on the positive effect of androgen priming on OS indicators and the clinical outcomes of in vitro fertilization (IVF). This review considers the main issues regarding the efficiency and safety of adjuvant pretreatment androgen therapy (regimens, dosages, and duration) on the effectiveness of ART cycles in poor female OS responders.
Conclusion: There is a need for further relevant randomized clinical trials to confirm the benefits and safety of androgen therapy before OS in poor female OS responders in the IVF programs.

Authors' contributions: Pshenisnova I.V., Yakovlev P.P. – concept and design of the investigation; Pshenisnova I.V. – material collection and processing, writing the text; Yakovlev P.P. – editing.
Conflicts of interest: The authors declare that there are no possible conflicts of interest.
Funding: The investigation has not been sponsored.
For citation: Pshenisnova I.V., Yakovlev P.P. Androgen priming in
a poor ovarian stimulation response..
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2023; (8): 22-29 (in Russian)


androgen priming
ovarian stimulation
poor ovarian stimulation response


  1. Zegers-Hochschild F., Adamson G.D., Dyer S., Racowsky C., de Mouzon J., Sokol R. et al. The international glossary on infertility and fertility care. Hum. Reprod. 2017;32 (9): 1786-801.
  2. Patrizio P., Vaiarelli A., Levi Setti P.E., Tobler K.J., Shoham G., Leong M. et al. How to define, diagnose and treat poor responders? Responses from a worldwide survey of IVF clinics. Reprod. Biomed. Online. 2015; 30(6): 581-92.
  3. Tarlatzis B.C., Zepiridis L., Grimbizis G., Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum. Reprod. Update. 2003; 9(1): 61-76.
  4. Loh S., Wang J.X., Matthews C.D. The influence of body mass index, basal FSH and age on the response to gonadotrophin stimulation in non-polycystic ovarian syndrome patients. Hum. Reprod. 2002; 17(5): 1207-11.
  5. Ferraretti A.P., La Marca A., Fauser B.C., Tarlatzis B., Nargund G., Gianaroli L.; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum. Reprod. 2011; 26(7): 1616-24.
  6. Luo S., Li S., Li X., Qin L., Jin S. Effect of pretreatment with transdermal tes-tosterone on poor ovarian responders undergoing IVF/ICSI: a meta-analysis. Exp. Ther. Med. 2014; 8(1): 187-94.
  7. Salam H.N., Ezzeldin F., Agameya A.F., Rahman A.F., El-Garem Y. Defining poor responders in assisted reproduction. Int. J. Fertil. Womens Med. 2005; 50(3): 115-20.
  8. Pandian Z., McTavish A.R., Aucott L., Hamilton M.P., Bhattacharya S. Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in in vitro fertilisation (IVF). Cochrane Database Syst. Rev. 2010; (1): CD004379.
  9. Casson P.R., Lindsay M.S., Pisarska M.D., Carson S.A., Buster J.E. Dehy-droepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum. Reprod. 2000; 15(10): 2129-32.
  10. Escriva A.M., Diaz-Garcia C., Monterde M., Rubio J.M., Pellicer A. Antral follicle priming before intracytoplasmic sperm injection in previously diagnosed low responders: a randomized controlled trial (FOLLPRIM). J. Clin. Endocrinol. Metab. 2015; 100(7): 2597-605.
  11. Alviggi C., Andersen C.Y., Buehler K., Conforti A., De Placido G., Esteves S.C. et al.; Poseidon Group (Patient-Oriented Strategies Encompassing Individualize DOocyte Number). A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil. Steril. 2016; 105(6): 1452-3.
  12. Polyzos N.P., Drakopoulos P., Parra J., Pellicer A., Santos-Ribeiro S., Tournaye H. et al. Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including ˜15,000 women. Fertil. Steril. 2018; 110(4): 661-70.e1.
  13. Esteves S.C., Alviggi C., Humaidan P., Fischer R., Andersen C.Y., Conforti A. et al. The POSEIDON griteria and its measure of success Through the Eyes of Clinicians and Embryologists. Front. Endocrinol. (Lausanne). 2019; 10: 814. 10.3389/fendo.2019.00814.
  14. Casson P.R., Lindsay M.S., Pisarska M.D., Carson S.A., Buster J.E. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum. Reprod. 2000; 15(10): 2129-32.
  15. Balasch J., Fabregues F., Penarrubia J., Carmona F., Casamitjana R., Creus M. et al. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum. Reprod. 2006; 21(7): 1884-93.
  16. Frattarelli J.L., Peterson E.H. Effect of androgen levels on in vitro fertilization cycles. Ferti.l Steril. 2004; 81(6): 1713-4.
  17. Nagels H.E., Rishworth J.R., Siristatidis C.S., Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst. Rev. 2015; (11): CD009749.
  18. Bosdou J.K., Venetis C.A., Kolibianakis E.M., Toulis K.A., Goulis D.G., Zepiridis L., Tarlatzis B.C. The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Hum. Reprod. Update. 2012; 18(2): 127-45.
  19. Гависова А.А., Кодылева Т.А., Назаренко Т.А. Применение тестостеронсодержащего геля при сниженном овариальном резерве у женщин с бесплодием в программах вспомогательных репродуктивных технологий (экстракорпоральное оплодотворение/интрацитоплазматическая инъекция сперматозоида). Проблемы репродукции. 2022; 28(5): 39 45. [Gavisova A.A., Kodyleva T.A., Nazarenko T.A. The use of testosterone-containing gel with reduced ovarian reserve in women with infertility in ART programs (IVF/ICSI). Russian Journal of Human Reproduction. 2022; 28(5): 39 45. (in Russian)].
  20. Гависова А.А., Камалетдинов Н.С., Назаренко Т.А., Долгушина Н.В. Применение андрогенного прайминга при сниженном овариальном резерве у женщин с бесплодием в программах вспомогательных репродуктивных технологий (ЭКО/ИКСИ). Акушерство и гинекология. 2022; 9: 94-101. [Gavisova A.A., Kamaletdinov N.S., Nazarenko T.A., Dolgushina N.V. The use of androgen priming in infertile women with diminished ovarian reserve undergoing assisted reproductive technology (IVF/ICSI). Obstetrics and Gynecology. 2022; (9): 94-101. (in Russian)].
  21. Яковлев П.П. Активность ароматазы Р450 яичников в естественном менструальном цикле и при стимуляции суперовуляции. Журнал акушерства и женских болезней. 2017; 66(5): 46-55. [Yakovlev P.P.Aromatase P450 activity in the natural menstrual cycle and during controlled ovarian stimulation. Journal of Obstetrics and Women’s Diseases. 2017; 66(5): 46-55. (in Russian)].
  22. Millier S.G., Whitelaw P.F., Smyth C.D. Follicular oestrogen synthesis: the “two-cell, two-gonadotrophin” model revisited. Mol. Cell. Endocrinol. 1994; 100(1-2): 51-4.
  23. Friis Wang N., Bogstad J.W., Pors S.E., Petersen M.R., Pinborg A., Yding Andersen C. et al. Eight weeks of androgen priming by daily low-dose hCG injections before ICSI treatment in women with low ovarian reserve. Hum. Reprod. 2023; 38(4):716-25.
  24. Nielsen M.E., Rasmussen I.A., Kristensen S.G., Christensen S.T., Møllgård K., Wreford Andersen E. et al. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol. Hum. Reprod. 2011; 17(1): 63-70.
  25. Rice S., Ojha K., Whitehead S., Mason H. Stage-specific expression of androgen receptor, follicle-stimulating hormone receptor, and anti-Müllerian hormone type II receptor in single, isolated, human preantral follicles: relevance to polycystic ovaries. J. Clin. Endocrinol. Metab. 2007; 92(3): 1034-40.
  26. Horie K., Takakura K., Fujiwara H., Suginami H., Liao S., Mori T. Immunohistochemical localization of androgen receptor in the human ovary throughout the menstrual cycle in relation to oestrogen and progesterone receptor expression. Hum. Reprod. 1992; 7(2): 184-90.
  27. Walters K.A., Handelsman D.J. Role of androgens in the ovary. Mol. Cell. Endocrinol. 2018; 465: 36-47.
  28. Weil S., Vendola K., Zhou J., Bondy C.A. Androgen and follicle stimulating hormone interactions in primate ovarian follicle development. J. Clin. Endo-crinol. Metab. 1999; 84(8): 2951-6.
  29. Vendola K.A., Zhou J., Adesanya O.O., Weil S.J., Bondy C.A. Androgens stimulate early stages of follicular growth in the primate ovary. J. Clin. Invest. 1998; 101(12): 2622-9.
  30. Vendola K., Zhou J., Wang J., Bondy C.A. Androgens promote insulin-like growth factor-I and insulin-like growth factor-I receptor gene expression in the primate ovary. Hum. Reprod. 1999; 14(9): 2328-32.
  31. Vendola K., Zhou J., Wang J., Famuyiwa O.A., Bievre M., Bondy C.A. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol. Reprod. 1999; 61(2): 353-7.
  32. Laird M., Thomson K., Fenwick M., Mora J., Franks S., Hardy K. Androgen stimulates growth of mouse preantral follicles in vitro: interaction with folli-cle-stimulating hormone and with growth factors of the TGFb super family. Endocrinology. 2017; 158(4): 920-35.
  33. Weil S.J., Vendola K., Zhou J., Adesanya O.O., Wang J., Okafor J., Bondy C.A. et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J. Clin. Endocrinol. Metab. 1998; 83(7): 2479-85.
  34. Feigenberg T., Simon A., Ben-Meir A., Gielchinsky Y., Laufer N. Role of androgens in the treatment of patients with low ovarian response. Reprod. Biomed. Online. 2009; 19(6): 888-98.
  35. Sunkara S.K., Pundir J., Khalaf Y. Effect of androgen supplementation or modulation on ovarian stimulation outcome in poor responders: a meta-analysis. Reprod. Biomed. Online. 2011; 22(6): 545-55.
  36. Zhang Y., Zhang C., Shu J., Guo J., Chang H.-M., Leung P.C.K. et al. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Hum. Reprod. Update. 2020; 26(2): 247-63.
  37. González-Comadran M., Durán M., Solà I., Fábregues F., Carreras R., Checa M.A. Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis. Reprod. BioMed. Online. 2012; 25(5): 450-9.
  38. Noventa M., Vitagliano A., Andrisani A., Blaganje M., Viganò P., Papaelo E. et al. Testosterone therapy for women with poor ovarian response undergoing IVF: a meta-analysis of randomized controlled trials. J. Assist. Rprod. Genet. 2019; 36(4): 673-83.
  39. Katsika E.T., Bosdou J.K., Goulis D.G., Grimbizis G.F., Kolibianakis E.M. Higher probability of live birth after testosterone pretreatment in women with poor ovarian response undergoing IVF: a systematic review and meta-analysis. Hum. Reprod. 2022; 37(Suppl. 1): deac105.027.
  40. Neves A.R., Montoya-Botero P., Polyzos N.P. Androgens and diminished ovarian reserve: the long road from basic science to clinical implementation. A comprehensive and systematic review with meta-analysis. Am. J. Obstet. Gynecol. 2022; 227(3): 401-13.e18.
  41. Bosch E., Broer S., Griesinger G., Grynberg M., Humaidan P., Kolibianakis E. et al.; The Eshre Guideline Group. ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum. Reprod. Open. 2020; 2020(2): hoaa009.
  42. Somboonporn W., Davis S.R., Seif M.W., Bell R.J. Testosterone for peri- and postmenopausal women. Cochrane Database Syst. Rev. 2005; (4): CD004509.
  43. Yeung T.W., Chai J., Li R.H., Lee V.C., Ho P.C., Ng E.H. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertil. Steril. 2014; 102(1): 108-115e1.
  44. Zhang H.H., Xu P.Y., Wu J., Zou W.W., Xu X.M., Cao X.Y. et al. Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing in vitro fertilization: a randomized controlled trial. J. Ovarian Res. 2014; 7: 93.
  45. Yeung T.W.Y., Li R.H.W., Lee V.C.Y., Chai J., Ng E.H.Y., Ho P.C. A randomized double-blinded placebo-controlled trial on the effect of 16 weeks of dehydroepiandrosterone (DHEA) on ovarian reserve markers and IVF outcomes in normal responders. Fertil. Steril. 2013; 100(3, Suppl.): S114.
  46. Artini P.G., Simi G., Ruggiero M., Pinelli S., Di Berardino O.M., Papini F. et al. DHEA supplementation improves follicular microenvironment in poor responder patients. Gynecol. Endocrinol. 2012; 28(9): 669-73.
  47. Massin N., Cedrin-Durnerin I., Coussieu C., Galey-Fontaine J., Wolf J.P., Hugues J.-N. Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique – a prospective, randomized, double-blind study. Hum. Reprod. 2006; 21(5): 1204-11.
  48. Wiser A., Gonen O., Ghetler Y., Shavit T., Berkovitz A., Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum. Reprod. 2010; 25(10): 2496-500.
  49. Kim C.H., Howles C.M., Lee H.A. The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertil. Steril. 2011; 95(2): 679-83.
  50. Hoang Q.H., Ho H.S., Do H.T., Nguyen T.V., Nguyen H.P., Le M.T. Therapeutic effect of prolonged testosterone pretreatment in women with poor ovarian response: a randomized control trial. Reprod. Med. Biol. 2021; 20(3): 305-12.

Received 29.04.2023

Accepted 04.07.2023

About the Authors

Irina V. Pshenisnova, obstetrician-gynecologist, MD Medical Yaroslavl,
Pavel P. Yakovlev, PhD, obstetrician-gynecologist, Centre for Reproductive Medicine, Co.Ltd. “Next Generation Clinic”, Moscow,,

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.